Naproxeno Gp

Naproxen, the active ingredient in Naproxeno Gp, is a nonsteroidal anti-inflammatory drug presented as an oral dosage form for oral use. It is used to relieve mild to moderate pain, reduce inflammation in conditions such as osteoarthritis and rheumatoid arthritis, and lower fever. GNH USA supplies Naproxeno Gp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naproxen is an NSAID that reduces inflammation and pain by inhibiting cyclooxygenase enzymes.

Mild to moderate pain: provides analgesic relief for headaches, dental pain, and musculoskeletal discomfort. Osteoarthritis and rheumatoid arthritis: decreases joint inflammation and improves mobility. Dysmenorrhea: alleviates menstrual cramps and associated pain. Fever: helps lower elevated body temperature.

Naproxen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Mild skin rash or itching.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation. - Renal impairment or acute kidney injury. - Severe hepatic dysfunction. - Life‑threatening skin reactions such as Stevens‑Johnson syndrome. - Anaphylaxis or severe hypersensitivity reactions.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor for adverse events.

Assess renal function: avoid use in patients with severe renal impairment. Monitor gastrointestinal risk: use cautiously in those with a history of ulcer disease. Check cardiovascular status: NSAIDs may increase risk of thrombotic events. Avoid concomitant anticoagulants: heightened bleeding risk. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Naproxen can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Selective COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: naproxen may raise lithium serum concentrations. - Methotrexate: potential for heightened methotrexate toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or diuretics: may reduce renal function, especially in volume‑depleted patients. - SSRIs or SNRIs: combined use can increase bleeding tendency.